Search for: "ACTAVIS" Results 581 - 600 of 1,006
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
13 May 2014, 5:00 am by Gene Quinn
Actavis plc (NYSE: ACT) announced yesterday that it has entered into an agreement with Valeant Pharmaceuticals International (NYSE: VRX) to settle all outstanding patent litigation related to Actavis' generic version of Acanya®... [read post]
5 May 2014, 8:28 am by Gene Quinn
The launch of Actavis’ product is contingent upon Actavis receiving final approval from the U.S. [read post]
2 May 2014, 9:43 am by Federal Trade Commission
The FTC brief explains that the no-authorized-generic (no-AG) commitment at issue raises the same antitrust concern that the Supreme Court identified in Actavis. [read post]
2 May 2014, 9:43 am by Federal Trade Commission
The FTC brief explains that the no-authorized-generic (no-AG) commitment at issue raises the same antitrust concern that the Supreme Court identified in Actavis. [read post]
2 May 2014, 5:00 am by Gene Quinn
Supreme Court Denies Teva's Request for an Injunction Relating to Generic Copaxone® --- Actavis Announces Celebrex® Patent Challenge Settlement --- Actavis Net Revenue Increases 40% to $2.66 Billion in First Quarter 2014. [read post]
2 May 2014, 5:00 am by Gene Quinn
Supreme Court Denies Teva's Request for an Injunction Relating to Generic Copaxone® --- Actavis Announces Celebrex® Patent Challenge Settlement --- Actavis Net Revenue Increases 40% to $2.66 Billion in First Quarter 2014. [read post]
25 Apr 2014, 1:45 am
"Wim van der Eijk observing howmuch the EPO empire has grownIPKat readers will note that Mr Justice Arnold has followed suit in his recent referrals, the Actavis v Sanofi judgment being one such instance. [read post]
22 Apr 2014, 4:51 pm by Dr. Shezad Malik
Wesley Davis, from New York filed a stroke product liability lawsuit against Actavis and Watson. [read post]
16 Apr 2014, 5:35 am by Ronald V. Miller, Jr.
Products in this category are: Androgel (Abbvie/Abbott) Androderm (Actavis) Axirom (Eli Lilly) Bio-T-Gel (BioSante and Teva) Delatestryl (Indevus) Depo-Testosterone (Pharmacia & Upjohn Company) Fortesta (Endo) Striant (Columbia Laboratories) Testim (Auxilum/GlaxoSmithKline) Testopel (Auxilium) Researchers have long suspected a link between testosterone treatment and the risk of heart attack, though millions of men who have been taking the hormonal treatments are just now learning of the… [read post]
7 Apr 2014, 8:53 pm by Aaron Barkoff
 Here is the complete agenda: On the 30th Anniversary of the Drug Price Competition and Patent Term Restoration Act: Understanding Hatch-Waxman's Transformative Impact on the Pharmaceutical Industry Assessing Pharmaceutical Patent Sustainability and Vulnerability: Strategies and Considerations for Brand Names and Generics in Anticipating, Identifying and Determining Which Patents Will be Ripe for Challenges of Invalidity and Non-Infringement Use of IPR and Other PTO Proceedings in a Paragraph… [read post]
6 Apr 2014, 10:00 pm by Courtenay Brinckerhoff
The Federal Circuit found that Roxane and Actavis did not have an express or implied license to practice... [read post]
4 Apr 2014, 9:32 am by Gene Quinn
The ultimate launch of Actavis’ product is, however, contingent upon Actavis receiving final approval from the U.S. [read post]
28 Mar 2014, 5:33 pm
.; Actavis, Inc.; Actavis Elizabeth, LLC; Cobalt Laboratories, Inc.; Cobalt Pharmaceuticals, Inc.; Sun Pharma Global, Inc; Sun Pharmaceutical Industries, Ltd.; Sun Pharmaceutical Industries, Inc.; Wockhardt Ltd.; and Mylan Pharmaceuticals, Inc. [read post]
26 Mar 2014, 3:25 pm
In Eli Lilly, Actavis provided an undertaking that they would not challenge validity. [read post]
24 Mar 2014, 10:39 am by Dr. Shezad Malik
Actavis, Inc., Androderm Endo Pharmaceuticals, Fortesta Testosterone Gel Auxilium Pharmaceuticals, Inc., Testim Testosterone Gel BioSante/Teva, Bio-T-Gel [read post]